Close

Jefferies Reinstates Zynerba Pharmaceuticals (ZYNE) at Buy

December 6, 2016 8:44 AM EST Send to a Friend
Jefferies reinstates coverage on Zynerba Pharmaceuticals (NASDAQ: ZYNE) with a Buy rating and a price target of $32.00.Analyst Biren Amin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login